Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis
Copyright © 2022 Elsevier B.V. All rights reserved..
BACKGROUND: Safety and effectiveness outcomes in Multiple Sclerosis (MS) patients receiving different disease-modifying therapies (DMT) and different types of vaccines against SARS-CoV-2 are limited. Growing evidence coming mainly from Israel, Europe and North America using mRNA and adenoviral vector vaccines has been published.
OBJECTIVES: To assess the safety and humoral response of inactivated virus and mRNA vaccines against SARS-CoV-2 in patients with MS.
METHODS: Ongoing, multicentric, prospective, observational study performed between February and September 2021. Humoral response (antibodies against spike-1 protein) was determined at least 4 weeks after the complete schedule of anti-SARS-CoV-2 vaccines. Categorical outcome (positive/negative) and total antibody titres were recorded. Adverse events supposedly attributable to vaccination (AESAV) were collected.
RESULTS: 178 patients, 68% women, mean age 39.7 ± 11.2 years, 123 received inactivated (Coronavac-Sinovac), 51 mRNA (Pfizer-BioNtech), and 4 adenoviral vector vaccines (CanSino n = 2, Jonhson&Johnson-Jannsen n = 1, Oxford-AstraZeneca n = 1). Six patients had a history of COVID-19 before vaccination. Overall humoral response was observed in 66.9% (62.6% inactivated vs. 78.4% mRNA, p = 0.04). Positive anti-S1-antibodies were observed in 100% of patients with no DMT (n = 3), 100% with interferon/glatiramer-acetate (n = 11), 100% with teriflunomide/dimethyl-fumarate (n = 16), 100% with natalizumab (n = 10), 100% with alemtuzumab (n = 8), 90% with cladribine (n = 10), and 88% with fingolimod (n = 17), while 43% of patients receiving antiCD20 (n = 99) were positive (38% inactivated vaccine vs. 59% mRNA vaccine, p = 0.05). In the multivariate analysis including antiCD20 patients, the predictors for a positive humoral response were receiving the mRNA vaccine (OR 8.11 (1.79-36.8), p = 0.007) and a lower number of total infusions (OR 0.44 (0.27-0.74) p = 0.002. The most frequent AESAV was local pain (14%), with 4 (2.2%) patients experiencing mild-moderate relapses within 8 weeks of first vaccination compared to 11 relapses (6.2%) within the 8 weeks before vaccination (Chi-squared 3.41, p = 0.06).
DISCUSSION: A higher humoral response rate was observed using the mRNA compared to the inactivated vaccine, while patients using antiCD20 had a significantly lower response rate, and patients using antiCD20 and fingolimod had lower antibody titres. In this MS patient cohort, inactivated and mRNA vaccines against SARS-CoV-2 appear to be safe, with no increase in relapse rate. This information may help guidelines including booster shots and types of vaccines in selected populations.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
---|---|
Enthalten in: |
Multiple sclerosis and related disorders - 59(2022) vom: 20. März, Seite 103690 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ciampi, Ethel [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 07.04.2022 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.msard.2022.103690 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM337147248 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM337147248 | ||
003 | DE-627 | ||
005 | 20231227130718.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.msard.2022.103690 |2 doi | |
028 | 5 | 2 | |a pubmed24n1225.xml |
035 | |a (DE-627)NLM337147248 | ||
035 | |a (NLM)35182880 | ||
035 | |a (PII)S2211-0348(22)00205-X | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ciampi, Ethel |e verfasserin |4 aut | |
245 | 1 | 0 | |a Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.04.2022 | ||
500 | |a Date Revised 13.12.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2022 Elsevier B.V. All rights reserved. | ||
520 | |a BACKGROUND: Safety and effectiveness outcomes in Multiple Sclerosis (MS) patients receiving different disease-modifying therapies (DMT) and different types of vaccines against SARS-CoV-2 are limited. Growing evidence coming mainly from Israel, Europe and North America using mRNA and adenoviral vector vaccines has been published | ||
520 | |a OBJECTIVES: To assess the safety and humoral response of inactivated virus and mRNA vaccines against SARS-CoV-2 in patients with MS | ||
520 | |a METHODS: Ongoing, multicentric, prospective, observational study performed between February and September 2021. Humoral response (antibodies against spike-1 protein) was determined at least 4 weeks after the complete schedule of anti-SARS-CoV-2 vaccines. Categorical outcome (positive/negative) and total antibody titres were recorded. Adverse events supposedly attributable to vaccination (AESAV) were collected | ||
520 | |a RESULTS: 178 patients, 68% women, mean age 39.7 ± 11.2 years, 123 received inactivated (Coronavac-Sinovac), 51 mRNA (Pfizer-BioNtech), and 4 adenoviral vector vaccines (CanSino n = 2, Jonhson&Johnson-Jannsen n = 1, Oxford-AstraZeneca n = 1). Six patients had a history of COVID-19 before vaccination. Overall humoral response was observed in 66.9% (62.6% inactivated vs. 78.4% mRNA, p = 0.04). Positive anti-S1-antibodies were observed in 100% of patients with no DMT (n = 3), 100% with interferon/glatiramer-acetate (n = 11), 100% with teriflunomide/dimethyl-fumarate (n = 16), 100% with natalizumab (n = 10), 100% with alemtuzumab (n = 8), 90% with cladribine (n = 10), and 88% with fingolimod (n = 17), while 43% of patients receiving antiCD20 (n = 99) were positive (38% inactivated vaccine vs. 59% mRNA vaccine, p = 0.05). In the multivariate analysis including antiCD20 patients, the predictors for a positive humoral response were receiving the mRNA vaccine (OR 8.11 (1.79-36.8), p = 0.007) and a lower number of total infusions (OR 0.44 (0.27-0.74) p = 0.002. The most frequent AESAV was local pain (14%), with 4 (2.2%) patients experiencing mild-moderate relapses within 8 weeks of first vaccination compared to 11 relapses (6.2%) within the 8 weeks before vaccination (Chi-squared 3.41, p = 0.06) | ||
520 | |a DISCUSSION: A higher humoral response rate was observed using the mRNA compared to the inactivated vaccine, while patients using antiCD20 had a significantly lower response rate, and patients using antiCD20 and fingolimod had lower antibody titres. In this MS patient cohort, inactivated and mRNA vaccines against SARS-CoV-2 appear to be safe, with no increase in relapse rate. This information may help guidelines including booster shots and types of vaccines in selected populations | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Observational Study | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Humoral response | |
650 | 4 | |a Multiple sclerosis | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a Vaccine | |
650 | 4 | |a inactivated virus | |
650 | 4 | |a mRNA | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
650 | 7 | |a COVID-19 Vaccines |2 NLM | |
650 | 7 | |a Vaccines, Synthetic |2 NLM | |
650 | 7 | |a mRNA Vaccines |2 NLM | |
650 | 7 | |a BNT162 Vaccine |2 NLM | |
650 | 7 | |a N38TVC63NU |2 NLM | |
700 | 1 | |a Uribe-San-Martin, Reinaldo |e verfasserin |4 aut | |
700 | 1 | |a Soler, Bernardita |e verfasserin |4 aut | |
700 | 1 | |a García, Lorena |e verfasserin |4 aut | |
700 | 1 | |a Guzman, Jorge |e verfasserin |4 aut | |
700 | 1 | |a Pelayo, Carolina |e verfasserin |4 aut | |
700 | 1 | |a Jürgensen, Lukas |e verfasserin |4 aut | |
700 | 1 | |a Guzman, Ignacio |e verfasserin |4 aut | |
700 | 1 | |a Vera, Francisco |e verfasserin |4 aut | |
700 | 1 | |a Galleguillos, Lorna |e verfasserin |4 aut | |
700 | 1 | |a Cárcamo, Claudia |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Multiple sclerosis and related disorders |d 2012 |g 59(2022) vom: 20. März, Seite 103690 |w (DE-627)NLM219118388 |x 2211-0356 |7 nnns |
773 | 1 | 8 | |g volume:59 |g year:2022 |g day:20 |g month:03 |g pages:103690 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.msard.2022.103690 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 59 |j 2022 |b 20 |c 03 |h 103690 |